These results supported the expansion into phase 2 clinical trials in both Ewing sarcoma and other Ewing-like tumors with other EWSR1 gene fusions, including myxoid liposarcoma, DSRCT, and clear cell sarcoma (105) (NCT03600649), which is currently still recruiting patients. The gene discussed is EWSR1; the disease is clear cell sarcoma.